Sign in
WithdrawnPhase 1

Evaluation Study of New Compounds With Potential Use in Schizophrenia

Key facts

Who runs it
Central Institute of Mental Health, Mannheim
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Phase 1
Started
31 Jan 2025
Ended
31 Jan 2025
Type of study
Interventional, 3 groups
Treatments tested
  • URB597
  • intranasal Insulin
  • Cannabidiol CR
Record updated
21 March 2025
Why it stopped
Lack of funding

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Healthy volunteers
  • Informed consent given by the subject
  • Both, female and male subjects may participate
  • Age between 18 and 65 years
  • Negative drug-screening at the time of screening
  • In female participants in fertile age, reliable contraception, which means contraception's pearl-index is equal or smaller than 1
  • Non-Smoker
  • Body Mass Index between 18 and 40

Who cannot take part

  • Consumption of any illegal drugs (except cannabis in history, see above)
  • Any current psychiatric disorder through the Structured Clinical Interview for DSM-IV (SCID) at the time of screening
  • Any known psychiatric or neurological illness in the participant's history
  • Known family history concerning psychiatric disorders
  • Severe physical (internal) or neurological illness, especially cardiovascular, renal, advanced respiratory, haematological or endocrinological failures or infectious diseases (acute hepatitis A, B or C or HIV) assessed at the time of the screening by the subject's history, clinical examination and laboratory testing, at the discretion of the investigator
  • Lack of accountability
  • Relevant use of cannabis (which is defined on the present state of knowledge as at the most five times lifetime-consumption and no consumption for at least one year)
  • Pregnancy or lactation phase in female at the time of screening

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Different compounds that might modify the glucose regulation in the central nervous system will be evaluated in healthy volunteers. Several examinations will be performed in order to get a detailed plan how these substances might work.

The 3 groups in the trial

  • Intranasal InsulinTreatment being tested

    Intranasal administered insulin

  • Cannabidiol CRTreatment being tested

    Cannabidiol is the main non psychoactive compound of the Cannabis sativa plant.

  • URB597Treatment being tested

    URB597 is a selective inhibitor of the Fatty acid amide hydrolase enzyme.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of Potential Central Glucoregulatory Compounds to Treat/Ameliorate the Symptoms of Schizophrenia: a Proof-of-concept Study in Healthy Volunteers.
Record updated
21 March 2025